RVL Pharmaceuticals plc (RVLPQ)
| Market Cap | 298.11K |
| Revenue (ttm) | 36.92M |
| Net Income (ttm) | -68.27M |
| Shares Out | 99.37M |
| EPS (ttm) | -0.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,883,599 |
| Open | 0.0026 |
| Previous Close | n/a |
| Day's Range | 0.0023 - 0.0044 |
| 52-Week Range | n/a |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About RVLPQ
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name t... [Read more]
Financial Performance
In 2022, RVLPQ's revenue was $49.72 million, an increase of 184.10% compared to the previous year's $17.50 million. Losses were -$51.69 million, -20.38% less than in 2021.
Financial StatementsNews
RVL Completes Financial Restructuring
Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities
RVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries
Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries ...
RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Exe...
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (ox...
RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review
-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendme...
RVL Pharmaceuticals plc to Discuss Second Quarter 2023 Financial Results and Provide Commercial Update
-- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET -- -- Conference call to be held Monday, August 14, 2023, at 8:30 a.m. ET --
RVL Pharmaceuticals plc Provides Business Update
BRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company organized in Ireland focused on the commerciali...
RVL Pharmaceuticals plc Announces Result of Proposal to Approve a Waiver of Offer Obligations under Rule 9 of the Irish Takeover Rules at Annual General Meeting
BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the proposal to app...
RVL Pharmaceuticals plc Reports First Quarter 2023 Financial Results; Provides Commercial Update
-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first ...
RVL Pharmaceuticals plc to Discuss First Quarter 2023 Financial Results and Provide Commercial Update
BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxy...
RVL Pharmaceuticals Announces that Upneeq® Wins “Best Eye Drop for Drooping Lids” NewBeauty in 13th Annual Beauty Awards
Selected from 10,000 Entrants Selected from 10,000 Entrants
RVL Pharmaceuticals plc Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Commercial Update
-- RVLP records exceptional year-over-year growth with UPNEEQ ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, o...
RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Commercial Update
Conference call to be held Monday, March 20, 2023, at 8:30 a.m. ET Conference call to be held Monday, March 20, 2023, at 8:30 a.m. ET
RVL Pharmaceuticals plc Announces Preliminary Fourth Quarter Sequential Growth of 21% and Full Year 2022 UPNEEQ® Net Product Sales
-- Expects fourth quarter 2022 preliminary UPNEEQ net product sales of approximately $12.1 million, representing an increase of 21% over the third quarter 2022, and approximately $36.5 million for ful...
RVL Pharmaceuticals plc to Present at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
BRIDGEWATER, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Exe...
RVL Pharmaceuticals plc Reports Third Quarter 2022 Financial Results; Provides Commercial Update
-- Third quarter 2022 UPNEEQ ® net product sales of $10.0 million; 19% above second quarter 2022; 355% above third quarter 2021 -- -- Approximately 3,500 cumulative unique medical aesthetics practices...
RVL Pharmaceuticals plc Announces Preliminary Third Quarter 2022 UPNEEQ® Net Product Sales
--Expects third quarter 2022 preliminary UPNEEQ net product sales of approximately $10.0 million, representing an increase of 19% over the second quarter 2022-- --Third quarter 2022 net product sales ...
RVL Pharmaceuticals plc to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Exe...
Revision Skincare® Announces Strategic Partnership with RVL Pharmaceuticals plc
DALLAS and BRIDGEWATER, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Revision Skincare®, a leading medical-grade professional skincare brand, announced today a partnership with RVL Pharmaceuticals plc (Nas...
RVL Pharmaceuticals plc Reports Second Quarter 2022 Financial Results; Provides Commercial Update
-- Second quarter 2022 UPNEEQ ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings --
RVL Pharmaceuticals plc Announces Insider and Athyrium-Led Financing
-- Secured $68.9 million in committed financing through a combination of equity and non-dilutive debt financing -- -- Cash runway anticipated to extend through 2023 with $43.9 million funded at closin...
RVL Pharmaceuticals plc to Discuss Second Quarter 2022 Financial Results and Provide Commercial Update
Conference call to be held Thursday, August 11, 2022, at 8:30 a.m. ET Conference call to be held Thursday, August 11, 2022, at 8:30 a.m. ET
RVL Pharmaceuticals plc Announces Preliminary Second Quarter 2022 UPNEEQ® Net Product Sales Results
-- Expects second quarter 2022 preliminary UPNEEQ net product sales of approximately $8.4 million, representing an increase of 42% from the first quarter 2022 -- -- Second quarter 2022 net product s...
RVL Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
BRIDGEWATER, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced results of the Company's Annua...
RVL Pharmaceuticals plc to Present at Upcoming Conferences
BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Exec...